Satoris

Satoris Inc. operates in the diagnostic equipment industry, with a focus on developing tests for neurological diseases. The company's mission is to create and commercialize neurodiagnostic tests that provide early and accurate diagnoses for conditions such as Alzheimer's disease. By offering these tests in a convenient and affordable manner, Satoris aims to improve patient outcomes.

The company's approach involves targeting the key neurotoxic mediators of Alzheimer's disease to develop therapies that can block its progression. One of its patented methods includes the diagnosis, stratification, and monitoring of Alzheimer's disease. Satoris has secured $5.9 million in funding from investors including Band of Angels, Brain Trust Accelerator Fund, Life Science Angels, and QB3. The company has since been acquired by Rules Based Medicine.

The leadership team included co-founder and Head of Research, Dr. Mark Findeis, and CEO Dr. Jeffrey Ives, a former Senior Vice President at Pfizer. Dr. Ives had a track record of leading teams that discovered numerous clinical candidates, including well-known products like Geodon®, Chantix®, and Tarceva®. This expertise was instrumental in guiding Satoris's focus on developing disease-modifying therapies.

Keywords: neurodiagnostics, neurology, diagnostic tests, Alzheimer's disease, disease-modifying therapies, neurodegenerative disorders, diagnostic equipment, clinical diagnosis, medical technology, life sciences, brain health, neurological research, biotechnology